Frankfurt
18.07.25 | 12:03
0,279 Euro
-5,74 % -0,017
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | FDA grants orphan status for AlzeCure's pain drug candidate | 3 | Pharmaceutical Business Review | ||
| Mi | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 200 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| Di | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 228 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.07. | The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares | 253 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 131 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 17.06. | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 294 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06. | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 261 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma: AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million | 336 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 12.06. | AlzeCure Pharma: AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease | 363 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 12, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 04.06. | AlzeCure Pharma to present at Redeye Investor Forum on June 11 | 276 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 03.06. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10 | 314 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 358 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 378 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 243 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen | |
| 09.04. | Notice to Annual General Meeting in AlzeCure Pharma AB | 414 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma: New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference | 425 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma publishes its Annual Report for 2024 | 388 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.04. | AlzeCure Pharma: New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity | 423 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 01.04. | AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 | 370 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2024 | 817 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 399,15 | -1,27 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement... ► Artikel lesen | |
| VIATRIS | 7,680 | +0,44 % | Why Is Viatris Stock Falling In Pre-market? | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment... ► Artikel lesen | |
| OPKO HEALTH | 1,185 | +2,40 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| ALTIMMUNE | 3,510 | -0,14 % | Altimmune, Inc: Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) | GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic... ► Artikel lesen | |
| JAGUAR HEALTH | 2,320 | 0,00 % | Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,550 | +1,44 % | SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study | The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,500 | +0,94 % | TD Cowen bekräftigt Kaufempfehlung für Aurinia Pharmaceuticals mit Kursziel von 11 US-Dollar | ||
| KIORA PHARMACEUTICALS | 3,180 | +0,95 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia | Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit... ► Artikel lesen | |
| LIPOCINE | 3,105 | -2,05 % | Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression | Phase 3 Top Line Results Expected Q2 2026
SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging... ► Artikel lesen | |
| PHOTOCURE | 5,370 | +10,38 % | Photocure ASA: Results for the first quarter of 2025 | OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,381 | -0,65 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 24,700 | -0,40 % | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy Paris, July 1st, 2025 Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME... ► Artikel lesen | |
| MEDICURE | 0,735 | 0,00 % | Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy | WINNIPEG, MB / ACCESS Newswire / June 17, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 27,670 | -1,07 % | Aktien der Woche: BASF, Bayer, Deutsche Rohstoff / Almonty, Evotec, Rheinmetall, Renk | Sechs Aktien sorgten in dieser Woche für Schlagzeilen - mit Kurssprüngen, Analystenreaktionen oder überraschenden Unternehmensmeldungen. Die 4investors-Redaktion zeigt, welche Titel in den letzten Tagen... ► Artikel lesen | |
| MERCK KGAA | 110,60 | -0,85 % | Verhaltene Kauflaune bei Merck KGaA-Aktie (112,35 €) | Wenig Kursbewegung derzeit bei dem Anteilsschein von Merck . Der jüngste Kurs betrug 112,35 Euro. Der Kurs der Aktie von Merck zeigt sich aktuell kaum verändert im Vergleich zu der letzten Notierung... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,74 % bei einem Aktienkurs von 0,279 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.